citric acid, anhydrous has been researched along with eptifibatide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arfsten, A; Jakubowski, JA; Jennings, LK; Longhurst, C; Nannizzi-Alaimo, L; Phillips, DR; Randolph, A; Scarborough, RM; Shattil, SJ; Teng, W; White, MM | 1 |
| Bozarth, JM; Forsythe, MS; Mousa, SA; Slee, A | 1 |
| Jordan, RE; Marciniak, SJ; Mascelli, MA | 1 |
| Kereiakes, DJ; Kukielka, G; Lorenz, T; Mueller, MN; Nanniazzi-Alaimo, L; Phillips, DR; Young, JJ | 1 |
| Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP | 1 |
1 trial(s) available for citric acid, anhydrous and eptifibatide
| Article | Year |
|---|---|
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
Topics: Abciximab; Acute Disease; Aged; Amino Acid Chloromethyl Ketones; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Citric Acid; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Kinetics; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2002 |
4 other study(ies) available for citric acid, anhydrous and eptifibatide
| Article | Year |
|---|---|
Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.
Topics: Antibodies, Monoclonal; Anticoagulants; Calcium; Citric Acid; Epitopes; Eptifibatide; Fibrinogen; Humans; Osmolar Concentration; Peptides; Plasma; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex | 1997 |
Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Calcium; Citric Acid; Eptifibatide; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Iodine Radioisotopes; Isoxazoles; Peptides; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Tirofiban; Tyrosine | 2000 |
Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Calcium; Chelating Agents; Citric Acid; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
Topics: Abciximab; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Blood Specimen Collection; Calcium; Chelating Agents; Citric Acid; Drug Interactions; Drug Monitoring; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Tirofiban; Tyrosine | 2001 |